Jan. 24, 2017 - A collaborative effort to improve the development of computational fluid dynamics (CFD) methodologies for evaluating "blood contacting" medical devices--receiving the Willem Kollf Award for top abstract at the ASAIO 2016 conference--is now reported in full in the ASAIO Journal, published by Wolters Kluwer.
The study describes two benchmark models evaluated by more than 20 independent groups using CFD techniques to predict blood flow patterns in circulatory support devices and other medical devices that come into contact with blood. The project is an important step toward using CFD to develop safer and more effective medical devices, according to the report by Richard Malinauskas, PhD, of the US Food and Drug Administration and colleagues.
Key Step Forward in Applying CFD Techniques to Medical Devices The international project to develop benchmark medical device flow models for CFD validation was presented at the ASAIO's 62nd annual conference, where it received the Top Abstract Award for 2016. The full report has now been posted on the website of the ASAIO Journal.
The FDA initiative sought to develop standardized methods for validating CFD simulations and predictions of blood damage for the safety evaluation of medical devices. Models of blood flow through typical device components were tested at multiple laboratories to provide robust experimental data on blood flow velocities and pressures, as well as on the likely damage to red blood cells (hemolysis).
The results showed some differences between simulated and measured blood flow values, and identified specific regions of the device models where discrepancies tended to occur. Under six test conditions in the blood pump model, 57 percent of the CFD simulation predictions of blood flow pressures were within one standard deviation of the measured values.
Dr. Malinauskas and co-authors note that only 37 percent of the 52 total CFD submissions for the two medical device models contained hemolysis predictions, indicating that more work is needed to develop widely-acceptable and credible hemolysis solvers. The collaborative project aided in the development of an FDA Guidance Document on factors to consider when reporting computational studies in medical device regulatory submissions to the FDA.
The study will be published in the March-April issue of ASAIO Journal and highlighted with a podcast and accompanying commentary. The paper will also be featured in an online journal collection of Top Abstract Award papers from each annual ASAIO conference.
The ASAIO 63rd annual conference will be held in Chicago, IL, June 21-24, 2017. The 2017 program theme is "Patient-Centric Innovation - Artificial Organs Beyond the Conventional." Abstract submission is now open; the deadline is February 9, 2017.
The top five abstracts will be chosen by executive committee and invited to present at the ASAIO conference. In order to be considered for the Willem Kollf Top Abstract Award, authors must submit complete manuscripts based on the abstracts by June 1, 2017.
Article: "FDA Benchmark Medical Device Flow Models for CFD Validation" (doi: 10.1097/MAT.0000000000000499)
About the Journal
ASAIO Journal, the official publication of ASAIO, is in the forefront of artificial organ research and development. On the cutting edge of innovative technology, it features peer-reviewed articles of the highest quality that describe research, development, the most recent advances in the design of artificial organ devices and findings from initial testing. Published bimonthly, the ASAIO Journal features state-of-the-art investigations, laboratory and clinical trials, and discussions and opinions from experts around the world.
About Wolters Kluwer
Wolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit http://www.